148 related articles for article (PubMed ID: 2937009)
21. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
22. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
23. Effect of electroimmobilisation on ovine plasma concentrations of beta-endorphin/beta-lipotrophin, cortisol and prolactin.
Jephcott EH; McMillen IC; Rushen J; Hargreaves A; Thorburn GD
Res Vet Sci; 1986 Nov; 41(3):371-7. PubMed ID: 2949354
[TBL] [Abstract][Full Text] [Related]
24. Functional opioid activity variates according to the different fashion of alcohol abuse.
Facchinetti F; Petraglia F; Nappi G; Martignoni E; Sinforiani E; Bono G; Genazzani AR
Subst Alcohol Actions Misuse; 1984-1985; 5(6):281-91. PubMed ID: 6100569
[TBL] [Abstract][Full Text] [Related]
25. Blood levels of haloperidol in schizophrenic patients.
Shvartsburd A; Dekirmenjian H; Smith RC
J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
[TBL] [Abstract][Full Text] [Related]
26. Clinical studies with synthetic ovine corticotropin-releasing factor.
Orth DN; DeBold CR; DeCherney GS; Jackson RV; Sheldon WR; Nicholson WE; Uderman H; Alexander AN; Island DP; Rivier J
Fed Proc; 1985 Jan; 44(1 Pt 2):197-202. PubMed ID: 2981741
[TBL] [Abstract][Full Text] [Related]
27. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
28. Effect of exogenous beta-endorphin on anterior pituitary hormone secretion in man.
Oyama T; Yamaya R; Jin T; Kudo T
Acta Endocrinol (Copenh); 1982 Jan; 99(1):9-13. PubMed ID: 6277126
[TBL] [Abstract][Full Text] [Related]
29. Plasma levels of beta-endorphin in young and aged human males during the morning hours.
Forman LJ; Cavalieri T; Fitzharris J; Chopra A; Marquis D; Estilow S
Horm Metab Res; 1987 Jan; 19(1):38-9. PubMed ID: 2951313
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal study of the effect, tolerance and undesired side effects of injection haloperidol decanoate applied in different psychiatric indications.
Zbytovský J; Zapletálek M
Act Nerv Super (Praha); 1989 Dec; 31(4):266-7. PubMed ID: 2638106
[No Abstract] [Full Text] [Related]
31. Haloperidol increases plasma beta endorphin-like immunoreactivity and cortisol in normal human males.
Murburg MM; Paly D; Wilkinson CW; Veith RC; Malas KL; Dorsa DM
Life Sci; 1986 Jul; 39(4):373-81. PubMed ID: 2942747
[TBL] [Abstract][Full Text] [Related]
32. Influence of yohimbine on release of anterior pituitary hormones.
Goldberg MR; Jackson RV; Krakau J; Island DP; Robertson D
Life Sci; 1986 Aug; 39(5):395-8. PubMed ID: 3016439
[TBL] [Abstract][Full Text] [Related]
33. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Deberdt R; Elens P; Berghmans W; Heykants J; Woestenborghs R; Driesens F; Reyntjens A; van Wijngaarden I
Acta Psychiatr Scand; 1980 Oct; 62(4):356-63. PubMed ID: 7468294
[TBL] [Abstract][Full Text] [Related]
34. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
Swigar ME; Jatlow PI; Goicoechea N; Opsahl C; Bowers MB
Am J Psychiatry; 1984 Oct; 141(10):1281-3. PubMed ID: 6486269
[TBL] [Abstract][Full Text] [Related]
35. Evidence for two differentially regulated populations of peripheral beta-endorphin-releasing cells in humans.
Murburg MM; Wilkinson CW; Raskind MA; Veith RC; Dorsa DM
J Clin Endocrinol Metab; 1993 Oct; 77(4):1033-40. PubMed ID: 8408451
[TBL] [Abstract][Full Text] [Related]
36. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL.
Hamann GL; Egan TM; Wells BG; Grimmig JE
J Clin Psychiatry; 1990 Dec; 51(12):502-4. PubMed ID: 1979555
[TBL] [Abstract][Full Text] [Related]
37. [Use of haloperidol at very high doses].
Lavagna J; Lafont A; Darcourt G
Encephale; 1976; 2(4):363-5. PubMed ID: 1001244
[TBL] [Abstract][Full Text] [Related]
38. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients.
Viukari M; Salo H; Lamminsivu U; Gordin A
Acta Psychiatr Scand; 1982 Apr; 65(4):301-8. PubMed ID: 7080851
[TBL] [Abstract][Full Text] [Related]
39. Steady-state plasma level prediction for haloperidol from a single test dose.
Javaid JI; Janicak PG; Hedeker D; Sharma RP; Davis JM
Psychopharmacol Bull; 1991; 27(1):83-8. PubMed ID: 1862210
[TBL] [Abstract][Full Text] [Related]
40. [Baths and their impact on the hypothalamo-hypophyseal axis].
Crielaard JM; Lorea V; Reuter AM; Vrindts Y; Pirnay F; Franchimont P
Acta Belg Med Phys; 1985; 8(2):95-9. PubMed ID: 2931936
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
